About this medicine

Mixed amphetamine salts contain both dexamfetamine and levamfetamine, also called dextroamphetamine and levoamphetamine in American sources. They can improve ADHD symptoms as part of a broader treatment plan, but are not interchangeable by name or dose with dexamfetamine alone.

The NHS SPS catalogue lists US-imported Adderall XR. NHS dm+d naming guidance and current pharmacy guidance identify Imported (country) entries as unlicensed imports. This supports a named-product import context, not a claim of routine NHS availability, exhaustive national licensing research or permission to obtain it independently.

What is this medicine used for?

The US immediate-release Adderall label includes ADHD and narcolepsy; the XR label covers ADHD, not the tablet's narcolepsy indication. Foreign age limits and indications must not be presented as UK approval.

UK unlicensed prescribing requires a specific clinical need and an evidence-based decision. Oxford Health's local formulary does not permit its clinicians to prescribe Adderall and directs people arriving from overseas towards specialist medicines advice about alternatives. That local restriction is not proof of a UK-wide ban or of what another service will fund.

Which warning signs need help?

Misuse can lead to addiction, overdose and death. Store the medicine securely, never share it and seek advice about disposal. The foreign FDA boxed-warning designation is not an MHRA warning category or a UK authorisation.

Chest pain, fainting, breathing difficulty, seizures, severe agitation, severe allergy or suspected overdose needs urgent or emergency assessment. Fever with confusion, sweating, tremor or rigid muscles can indicate serotonin toxicity and also needs urgent assessment.

New hallucinations or mania, worsening tics and cold, painful or discoloured fingers or toes require review. Seek immediate help if behaviour becomes dangerous or the person cannot remain safe.

How do I take it safely?

The reviewed NHS import entry is a modified-release capsule. The separate US immediate-release tablet label does not establish current UK tablet availability or a nationally available strength range.

For the US XR capsule, the label permits swallowing whole or sprinkling the entire contents on apple sauce and swallowing promptly without chewing. Do not crush the beads, divide the contents or store the mixture. A pharmacist must confirm the actual supplied product and directions; no automatic conversion to another amfetamine preparation is given.

What side effects should I know about?

Reduced appetite, weight loss, dry mouth, headache, nausea, abdominal pain, disturbed sleep, nervousness and a faster heartbeat can occur. Emotional changes also deserve attention.

Persistent adverse effects should prompt discussion of tolerability and benefit. A family member's experience or a different stimulant's side-effect profile cannot predict an individual's response to this mixture.

Who needs extra care with this medicine?

The foreign labels contraindicate hypersensitivity to the product and MAOI treatment, including within fourteen days after an MAOI is stopped. Serious cardiac disease can make stimulant treatment unsafe.

Assessment should consider blood pressure, cardiac and family sudden-death history, seizures, bipolar or psychotic illness, tics, poor growth and vulnerability to misuse. Kidney impairment is particularly important for exposure. This selected list cannot establish eligibility for an imported medicine.

Can it affect my other medicines?

MAO inhibitors can cause a dangerous rise in blood pressure. Serotonergic medicines and CYP2D6 inhibitors can increase serotonin-toxicity risk. Examples requiring particular attention include relevant antidepressants and medicines such as linezolid; all recent medicines matter.

Urine-acidifying agents can lower amfetamine exposure, while alkalinising agents can raise it. Do not manipulate urine acidity or take supplements to alter the effect. Review decongestants, other stimulants, blood-pressure medicines and non-prescription products with the clinician or pharmacist.

What check-ups will I need?

Follow-up should assess symptoms and everyday functioning, sleep, appetite, weight, blood pressure and pulse. Children also need growth assessment. Review mental state, tics, adherence, adverse effects and misuse concerns rather than increasing treatment automatically.

For an unlicensed supply, responsibility for prescribing, monitoring and communication must be agreed. Someone moving between countries should not assume that an overseas prescription automatically becomes a UK repeat prescription. This article does not give a fixed UK monitoring timetable.

What about pregnancy, breastfeeding and age?

Pregnancy planning and exposure need a benefit–risk discussion. Observational evidence has limitations; prematurity, fetal growth and newborn withdrawal are considerations alongside the effects of untreated illness.

Amfetamines enter breast milk. The current US XR label advises against breastfeeding during treatment because of potential infant effects; this is explicitly foreign product advice, requiring an individual treatment and feeding plan.

Children need growth and appetite monitoring. The US XR product is not recommended below six years; that must not be transferred into a UK licensed age claim. Experience in older adults is limited.

What if I miss a dose or want to stop?

After prolonged use, abrupt stopping or a large reduction can cause low mood, fatigue, disturbed sleep, increased appetite and slowing or agitation. Arrange changes with the prescriber and seek urgent help for severe depression or inability to stay safe.

Follow the actual preparation's missed-dose instructions and never double. The US XR advice avoids a late catch-up dose because it may disrupt sleep; this is not a substitute for checking the directions on an imported supply.

How does it work?

Mixed amfetamine salts change how nerve cells handle dopamine and noradrenaline, two chemical messengers. They increase release of these messengers and reduce reuptake, their return into cells after release. More can then remain available to act between cells, although the full pathway to improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms is not established.

These medicines can also affect pulse, blood pressure, appetite and sleep. Feeling more alert after a stimulant, a medicine that increases activity in certain brain and body signalling systems, does not diagnose ADHD. The person’s development, everyday difficulties and other possible explanations still matter when deciding what those difficulties mean.

How does it affect my body?

Pharmacodynamics describes what a medicine does to the body. In ADHD, the intended benefit concerns attention, impulsivity and day-to-day functioning. In the foreign immediate-release narcolepsy indication, the target is excessive sleepiness.

Benefit should be assessed alongside sleep, appetite and participation in daily life. Anxiety, abdominal discomfort, insomnia and increased heart rate may offset improvement. A higher dose does not guarantee better function.

How does my body process it?

Pharmacokinetics describes absorption, breakdown and removal. XR beads release part of the medicine promptly and part later. The two enantiomers have different elimination profiles; extended release is not equivalent to simply taking an immediate-release tablet later.

Kidney elimination and urine acidity affect exposure, and CYP2D6 contributes to metabolism. Kidney or liver impairment can prolong exposure. Foreign renal-adjustment instructions are product-specific and are not reproduced as an invented UK regimen.

How do treatment options differ?

Mixed salts deliver a d/l mixture directly; dexamfetamine alone has a different active composition. Release systems also differ between immediate-release tablets, XR capsules and other amfetamine products.

Matching the ingredient family, a brand name or a milligram number is not a safe conversion method. An alternative treatment needs individual assessment of the exact formulation, response and regulatory context, not a search-alias match.

A closer look at the science

The four salts deliver the same amfetamine skeleton in two mirror-image forms, with about three parts d-amfetamine to one part l-amfetamine. Salts, active-base amounts and the names of other stimulants are not automatically equivalent.

The NHS catalogue's description of amfetamine plus dexamfetamine should not be mistaken for an equal ratio of the two mirror-image forms: the amfetamine component itself contains both. A mixture's identity must be checked before any comparison or proposed switch.

How was this medicine developed?

Immediate-release and XR products represent different stages in delivery-system development: adding delayed release changes the exposure pattern without making the mixture a different set of active enantiomers. Historical brand recognition should therefore not be treated as proof that every preparation is equivalent.

The reviewed US immediate-release label was updated in 2024 and the XR label in 2026. Their safety and population boundaries need current checking. The UK catalogue's import designation and a local NHS service's prescribing policy address separate questions from US authorisation.

Sources and References

  1. Adderall XR 5mg capsules (Imported (United States)): actual medicinal product

    Scope: United Kingdom medicine catalogue; named US-imported product.

  2. Adderall XR: current US prescribing information

    Scope: United States; foreign formulation, science and safety evidence only.

  3. Adderall immediate-release tablets: US prescribing information

    Scope: United States; foreign product distinction and science only.

  4. Dextroamphetamine and amphetamine: patient medicine information

    Scope: United States; general safety education only.

  5. Oxford Health NHS Foundation Trust formulary: ADHD medicines

    Scope: Oxford Health local service, England; not a national formulary decision.

  6. dm+d Implementation Guide (Primary Care), version 2.0

    Scope: England prescribing terminology; UK medicine-product catalogue context.

  7. Unlicensed specials and imports

    Scope: England electronic prescription and dispensing terminology.

  8. Understanding unlicensed medicines

    Scope: United Kingdom medicines governance.

  9. Prescribing unlicensed medicines

    Scope: United Kingdom professional prescribing standards.

  10. Schizophrenia
  11. NIMH: Understanding psychosis
  12. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  13. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top